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Study Objectives: (a) To describe the microarchitecture of wakefulness and sleep 
following administrations of 5- and 10-mg/kg AM-251 in rats. (b) To develop a new 
statistical method to follow bout-to-bout dynamics.
Method: Wistar rats (n = 6) had been equipped with electroencephalography (EEG) 
and electromyography (EMG) electrodes. Following their recovery and habituation 
after the surgery, the animals were injected with vehicle and 5- and 10-mg/kg AM-251 
intraperitoneally and EEG, EMG, and motor activity were analyzed for the subsequent 3 h.
Results: AM-251 induced a dose- and time-dependent increase in the number of bouts 
in active wake (AW), and it decreased this number in all other vigilance states except in 
passive wake (PW). In contrast, the bout duration in PW compensatory decreased. The 
effect of AM-251 on the sleep transition dynamics was monitored with a new tool we call 
“transition heatmap.” The analysis of bout trajectories with transition heatmaps reveals a 
highly organized pattern.
Conclusion: AM-251 selectively influences the frequency of vigilance state transitions, 
but it has no direct impact on the state lengths. AM-251 markedly changed the state 
transition dynamics, which was visualized with the help of state transition heatmaps.
Keywords: sleep–wake behavior, AM-251, sleep cycle, cannabinoid receptor, heatmap, REM sleep
INTRODUCTION
Analyses of sleep–wake behavior have already confirmed that antagonizing CB1 and CB2 
receptors disrupt the normal sleep pattern, although the results are contradictory. Suppression 
of rapid eye movement sleep (REMS) in rats has been reported with dronabinol, a nonselective 
CB1/CB2 antagonist (Calik and Carley, 2017), but also with the CB1 receptor–selective antagonist 
AM-251 (Santucci et al., 1996; Goonawardena et al., 2011). The REMS-reducing effect has been 
confirmed in mice too with the application of the CB1 receptor antagonists AM-251 and ABD459 
(Goonawardena et al., 2015). However, regarding non-REM sleep (NREMS) states, Santucci et al. 
have found in rats that the amount of wakefulness is increased at the expense of slow-wave sleep 
(S), while Goonawardena et al. could not confirm this effect either in rats (Goonawardena et al., 
2011) or in mice (Goonawardena et al., 2015). In line with this, neither the total amount nor 
the bouts of lengths of NREMS and wake episodes were affected by any receptor-selective and 
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non-selective antagonists on the CB1 and CB2 receptors (Calik 
and Carley, 2017). In the latter studies, only three vigilance states 
(wakefulness, NREMS, and REMS) were distinguished (Santucci 
et al., 1996; Goonawardena et al., 2011; Goonawardena et al., 
2015; Calik and Carley, 2017). Furthermore, both the number 
and bout duration data of vigilance states in treatment groups 
were compared with standard statistical tools, which have 
been developed for normally distributed data. However, it has 
been suggested recently that the application of more advanced 
statistical methods to model bout sequence allows a better 
insight into the underlying physiological mechanisms. Several 
methods have been proposed, such as survival analysis (Klerman 
et al., 2013), Markov chains (Bizzotto et al., 2010; Kostyalik et al., 
2014), and state-space technique (Diniz Behn et al., 2010). It has 
also been observed that vigilance states, previously thought to 
be homogenous, can be further differentiated by the duration 
of bouts. Simasko et al. and McShane et al. have distinguished 
short and long wake bouts (Simasko and Mukherjee, 2009; 
McShane et al., 2010). Moreover, McShane et al. have argued that 
distributions of every standard vigilance state, such as REMS, 
NREMS, and wakefulness, can be decomposed into spikes (short 
but frequent bouts) and slabs (long-lasting but rare bouts). They 
have also showed that the bout characteristics depend on the 
previous states (McShane et al., 2013). Clearly, there is a sharp 
contradiction between the requirements of distinguishing more 
sleep states and using more sophisticated models. For example, 
a Markov chain model with six states such as active wake (AW), 
passive wake (PW), light-, and deep slow-wave sleep (S1 and S2, 
respectively), REMS and intermediate stage of sleep (IS) requires 
36 parameters to be estimated if it is assumed that any state is 
achievable from any other. If additional time or drug effects 
are assumed, the number of parameters is multiplied further, 
so estimating all of them would be practically impossible. 
Typical solutions to resolve this conflict are i) restricting the 
number of states (like wake, REMS, and NREMS) or ii) setting 
some parameters arbitrarily to zero. Therefore, there is a clear 
need for analyses that are model-independent, yet still more 
informative than the commonly used statistics. McShane et al. 
(2013) suggested the application of three summary parameters 
for this purpose: i) the number of bouts—that is, conditional 
on the previous states; ii) the number of spikes (short bouts); 
and iii) the mean duration of long bouts. In this work, the 
applicability of the new explorative approach by McShane et al. 
(2013) is illustrated using our data. Additionally, prompted by 
the nature of the data itself, we propose new tools for explorative 
sleep state analysis.
METHODS
Animal Maintenance
All animal experiments and housing conditions were carried 
out in accordance with the EU Directive 2010/63/EU and the 
National Institutes of Health “Principles of Laboratory Animal 
Care” (NIH Publications No. 85-23, revised 1985), as well as 
specific national laws (the Hungarian Governmental Regulations 
on animal studies 40/2013). The experiments were approved 
by the National Scientific Ethical Committee on Animal 
Experimentation. Male Wistar rats (n = 6) were provided by the 
Animal Facility (Semmelweis University, Budapest, Hungary). 
During the whole period of the experiment, the rats were kept 
under controlled environmental conditions (21 ± 1°C, 12 h/12 h 
light–dark cycle with light on at 10 am); food and water were 
available ad libitum during the whole experiment. On the day 
of the EEG surgery, the rats weighed 300–330 g. All efforts were 
made to minimize pain and discomfort of the rats.
Surgery
The rats were chronically implanted with stainless steel screw 
electroencephalographic (EEG) electrodes epidurally. The surgery 
was performed under halothane (2%) anesthesia (Fluotec 3 
vaporizer) using a Kopf stereotaxic instrument. For frontoparietal 
EEG recordings, the positions of the electrodes were: left frontal 
cortex (L = 2.0 mm and A = 2.0 mm to bregma) and left parietal 
cortex (L = 2.0 mm and A = 2.0 mm to lambda), as described 
earlier (Kantor et al., 2002). Also, a ground electrode was placed 
over the cerebellum. To detect muscular activity, stainless steel 
spring electromyographic (EMG) electrodes embedded in silicon 
rubber (Plastics One Inc., Roanoke, VA, USA) were implanted 
into the neck muscles on both sides. Following the implantation 
surgery, the rats were kept in a square glass recording chamber 
separately during the whole experiment.
Drug Administration
AM-251 (AM, N-[Piperidin-1-yl]-5-[4-iodophenyl]-1-[2,4-
dichlorophenyl]-4-methyl-1H-pyrazole-3-carboxamide) was 
purchased from Tocris Cookson (Bristol, UK). The vehicle of 
AM-251 was composed of the mixture of 70% PBS (phosphate 
buffered saline, pH = 7.4), 20% dimethyl sulfoxide, and 10% 
Tween 80. The rats were treated with an intraperitoneal (i.p.) 
injection of 5- or 10-mg/kg AM-251 or vehicle (Veh) at the 
beginning of passive phase (at 10 am). All rats were given all 
treatments in a cross-over design with 3 days washout.
EEG Recording
After a 7-day recovery period, the rats were attached to the EEG 
system by a flexible recording cable and an electric swivel, fixed 
above the cages, permitting a free movement of the animals. 
The animals were attached to the EEG system a week before 
starting the cross-over of treatments and were kept connected 
to the system during the whole experiment. To detect the motor 
activity of the rats, electromagnetic transducers were used, in 
which potentials were generated by movements of the recording 
cable (Kantor et al., 2002). EEG, EMG, and motor activities 
were recorded during a 24-h-long period, starting at light onset. 
During the EEG recordings, the rats were undisturbed and had 
free access to standard rodent chow and tap water. The signals 
were amplified by analogue filters (Coulburn Lablinc System, 
USA; filtering below 0.50 Hz and above 100 Hz at 6 dB/octave) 
and subjected to analogue to digital conversion (MVRD-2200 V, 
Canopus, Japan) with a sampling rate of 256 Hz. Data were stored 
on a computer for further processing.
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Sleep Scoring
The vigilance states were analyzed using a semi-automatic 
method. First, we ran an automatic stage-scoring using SleepSign 
for Animal software for 4-s epochs (Kissei Comtec America, 
Inc., USA). It was followed by visual supervision. The following 
vigilance stages were classified based on a previous work of 
our laboratory (Kantor et al., 2002)—active wakefulness (AW): 
the EEG is desynchronized showing low-amplitude activity at 
beta (14–30 Hz) and alpha (8–13 Hz) frequencies accompanied 
by high EMG and intense motor activity; passive wakefulness 
(PW): the EEG is characterized by low-amplitude activity at 
beta (14–30 Hz) and alpha (8–13 Hz) frequencies accompanied 
by high EMG activity but minimal or no motor activity; 
light slow-wave sleep (S1): high-voltage slow cortical waves 
(0.5–4 Hz) interrupted by spindles (6–15 Hz) and accompanied 
by reduced EMG and no motor activity; deep slow-wave sleep 
(S2): with continuous high-amplitude slow cortical waves 
(0.5–4 Hz), minimal EMG, and no motor activity; REMS: 
desynchronized EEG activity with regular theta waves (5–9 Hz) 
were accompanied by silent EMG and motor activity with 
occasional muscular twitching; and IS: a brief stage just prior to 
or after REMS, characterized by an unusual association of high-
amplitude spindle activity (mean 12.5 Hz) with low-frequency 
(mean 5.4 Hz) theta rhythm. The latency of NREMS was 
calculated as the time elapsed between the drug administration 
and the occurrence of the first consecutive NREMS (S1, S2, and 
IS) episode lasting at least 3 min and not interrupted by more 
than 14 consecutive 4-s epochs, or a cumulated total of 240 s not 
scored as NREMS (Huber et al., 1998).
Statistical Analysis
This study is a three-period crossover design study with repeated 
measurements within the periods. A simple linear model was 
applied to assess the dependence of the response variables (bout 
number, bout durations, total sleep time) on the explanatory 
variables (treatment and time). The variable “treatment” was a 
categorical variable with three levels corresponding to three 
doses: 0, 5, and 10 mg/kg, respectively. The observation period 
was split into three intervals (1st h, 2nd h, and 3rd h), and the 
resulting time variable was included into the statistical model 
as an unordered categorical variable. Thus, the statistical model 
for bout numbers and bout durations had three independent 
variables: “treatment” and “time” as fixed factors and “animals” 
as a repeated measure variable.
Crossover design studies can be analyzed with repeated 
measures ANOVA or with mixed linear regression. The regression 
approach is more versatile and can be used even for not normally 
distributed response variables. Because of that, we chose the 
second option. The bout frequency was assumed following 
overdispersed Poisson distribution, and a mixed regression 
model variant called “negative binomial mixed regression” was 
used to handle overdispersion. Bout durations and total times 
were logarithmically transformed before fitting a regression 
model since their distributions were heavily right skewed.
Regression models were fitted with and without the 
variable “treatment” to evaluate the significance of the overall 
treatment effect. The assessment is based on F-test since the 
ratio of the corresponding residual mean squares follows F 
distribution. Using contrasts, the overall treatment effect was 
split into two parts corresponding to the differences between 
the effects of the 10-mg dose versus the Veh and of the 5-mg 
dose group versus the Veh. The difference estimates divided 
by their standard errors follow t-distribution, which allowed 
testing the treatment effects by simple t-tests at each dose 
level. We report the nominal p values without multiplicity 
adjustments because the applied two-step testing strategy 
controls the overall type I error. The difference estimates 
following fitting negative binomial regression models were 
raised to power because, in this form, they have a clear 
meaning: they show the bout numbers relative to the control. 
For practical significance assessment, we plotted them 
with the corresponding 95% confidence intervals. For bout 
duration, the parameter of interest was the time × treatment 
interaction, but the meaningful interpretation of the regression 
parameters was not straightforward. Therefore, we computed 
the 95% confidence intervals of the model predicted means to 
visualize the difference between the treatment groups. Lack of 
overlap between confidence intervals was taken as evidence 
of significant differences between treatments in the three 
time intervals. The linear model for “total time” had only 
one exploratory variable (treatment). In this special case, our 
testing approach is equivalent to what is known otherwise as 
one-way repeated measures ANOVA with random effects.
To study the conditional dependence of vigilance states, 
first, we cross-tabulated the number of bouts by the type of 
predecessor bouts. Tables obtained in this way were perceived 
as contingence tables between two nominal variables. Instead 
of the overall independence hypothesis (transitioning from 
any state to any other state is equally likely), we focused on 
the question of how likely it is that “state j” follows “state i.” 
This probability was estimated by calculating the standardized 
difference between the observed and expected probabilities 
for each cell in the table. Here “expected” means “according 
to the independence null hypothesis.” The resulting z-statistics 
asymptotically follows normal distribution, and values larger 
than 2 and smaller than -2 are usually considered as signs of 
significant dependence. The z-statistics cannot properly be 
estimated if there are less than five observations and, in such 
cases, z was not calculated. The idea of visualizing dependence 
between categories with the help of the z-statistics is coming 
from (Friendly, 1999). We used the freely available R software 
for computation and visualization (R Core Team, 2018) with 
several additional libraries including ggplot2 (Wickham, 2016) 
and lme4 (Bates et al., 2015).
RESULTS
AM-251 Increases the Total Time Spent in 
Wakefulness
The percentages of total time spent in vigilance states in the first 
3 h after the treatment with the different doses of AM-251 is 
displayed in Figure 1. The amount of wakefulness is increased 
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at the expense of REMS and NREMS stages. Figure 1 shows a 
clear dose-dependence in the effect of AM-251, although a 
detailed statistical analysis showed that only the higher dose had 
significant effect in AW (t = 2.55, df = 50, p = 0.014), REM sleep 
(t = 2.19, DF = 28, p = 0.029), and S2 (t = 2.53, DF = 51, p = 
0.0148). Despite the NREMS-suppressing effect of AM-251, the 
latency of NREMS did not change (repeated measures one-way 
ANOVA: F 2,10 = 0.4204, p = 0.6679).
Shape Analysis of the Distribution of Bout 
Duration in Different Vigilance Stages
Histograms of bout durations in units of 4-s epochs are presented 
in Figure 2. As expected, the distributions are heavily right-
skewed. Spikes (short, high frequency bouts) and slabs (long, 
low-frequency bouts) described by McShane et al. (2010) in 
mice can be observed in case of AW, PW, S1, and particularly 
in REMS. Therefore, we reclassified bouts of REMS as “short” 
FIGURE 1 | The percent of the time spent (means ± SEM, N = 6 per groups) in vigiliance states during the first 3 hours following intraperitioneal injections of vehicle 
(Veh) and AM-251 in 5-mg/kg (AM-5) and 10-mg/kg (AM-10) doses. Note that the larger dose significantly increased the time spent in active wake and decreased 
the time spent in rapid eye movement sleep and deep slow-wave sleep compared to the Veh group. *p < 0.05 compared to Veh.
FIGURE 2 | Histograms of bout durations of each vigilance stage. The Y axis shows the total counts of bouts in units of 4-s epochs during the 3-h-long observation 
period. The distributions of bout durations in rapid eye movement sleep (REMS) have two distinct components: a very short and relatively frequent bout, referred as 
“short REMS bout” (REMS-S) and the much longer and less frequent “long REMS bout” (REMS-L).
AM-251 and SleepBogáthy et al.
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(maximum length is 16 s, 4 epochs, REMS-S) and long REMS 
bouts (REMS-L). However, no major differences can be observed 
between the shapes of distributions in different treatment groups 
(Figure 2). If AM-251 had major effect on the bout durations, 
then histograms of treated groups would be shifted relative to the 
control. There is no sign of that in Figure 2.
The Effect of AM-251 on Bout Frequencies
The 3-h observation periods were divided into three segments, 
and the number of bouts by treatment groups is shown in Figure 3. 
A clear dose and time dependency can be observed additionally 
to circadian variation shown by the control group. Therefore, the 
time- and subject-adjusted bout frequency ratios are reasonable 
parameters to assess the drug effect. Figure 4 gives the frequency 
ratios with the corresponding 95% confidence intervals. AM-251 
applied in 5-mg/kg dose significantly suppressed the occurrence 
of REMS-L bouts and moderately increased the number of AW 
bouts. In the larger dose, AM-251 increased the number of AW 
bouts and decreased the number of bouts in all other vigilance 
states except PW. The effect on REMS-L is not significant, but it is 
still on the same level as with the lower dose (Figure 3).
Effect of AM-251 on Bout Durations
Bout durations were analyzed by mixed linear regression 
following logarithmic transformation. The independent variables 
in the regression equation—time and treatment—were declared 
FIGURE 3 | Dose-dependent effect of AM-251 on the number of bouts in different vigilance stages. Vehicle (Veh) or AM-251 was injected intraperitoneally at the 
beginning of passive phase in 5- and 10-mg/kg doses (AM-5 and AM-10). The 3-h length observation periods were divided into three 1-h intervals, and the bars 
show the number of episodes as means ± SEM (of N = 6 rats) by these intervals.
FIGURE 4 | Bout frequency ratios were estimated with negative binomial regression. The figure shows the estimated ratios with the corresponding 95% confidence 
intervals. The effect is significant if the confidence interval crosses the red line (where the ratio is 1), which is corresponding to the “no effect” (also called null 
hypothesis).
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as categorical variables (i.e., factors). Significance of the variables 
was again evaluated by comparing residual mean squares. Each 
vigilance state was analyzed this way.
The treatment effect of AM-251 was significant only in PW 
(F = 15.07, DF = 2, 1,352, p < 0.001) and moderate in S1 (Figure 5). 
In case of S1, only the 10-mg/kg dose of AM-251 had significant 
effect (t = 2.19, DF = 1,245, p = 0.0287). The interpretation of 
these statistical results is not straightforward; so, to get a better 
understanding, we plotted the observed means with the model 
predicted 95% confidence intervals (shown by colored stripes). 
Surprisingly, Figure 5 shows a time trend that is the opposite of 
what we have seen in the frequency analysis (Figure 3). There 
is no difference between the groups in the first hour; so, the 
confidence intervals are overlapping completely. In the next 2 h, 
the bout durations decrease in each group; however, the decrease 
is much faster in the 10-mg/kg dose group than in the other two, 
particularly between the first and second hours. At the end of the 
observation period, the confidence intervals are clearly separated 
in left the panel (PW) of Figure 5 but not in the right panel (S1), 
though the trend is similar in both panels. Extending the model 
with a time × treatment interaction term, this interaction was 
significant only for PW, and only in the 10-mg/kg dose group 
(F = 5.07, DF = 4, 1,350, p < 0.001).
Sleep Microarchitecture Analysis
Both the frequency and duration of bouts conditionally depend 
on the characteristics of the previous bout (McShane et al., 
2010; Bizzotto and Zamuner, 2018; Stephenson et al., 2013). 
For example, durations of REMS bouts depend on whether the 
previous state is wake or NREMS (McShane et al., 2010). Also, 
the probability that the next bout will be an REMS bout depends 
on whether the current state is wake or NREMS (McShane 
et al., 2013). Statistically speaking, the bout characteristics 
conditionally depend on the type of the preceding bout. Figures 3 
and 4 demonstrate that AM-251 modulates bout frequencies 
rather than bout durations; however, this shows only an overall 
picture, by averaging the conditional effect. Figures 3 and 4 
do not provide information about the frequency of the state 
transitions that conditionally depends on the previous state. This 
statistical problem can be reformulated using pharmacological 
terminology: given that the animal is now in PW, how does 
AM-251 influence the chance whether the next stage would be 
AW and not S1? Or generally, how does the treatment divert the 
normal transition pathways? To answer these questions, first, we 
cross-tabulated the bout frequencies for every hour of the three-
hour observation period and for each treatment. As a result, 
we got nine contingency tables which contained zeros in the 
diagonals due the variable definitions. In the next step, similarly 
to Kishi et al. (2008), we calculated the observed transition 
probabilities by dividing the table entries with the total number 
of state transitions. The observed transition probabilities can be 
directly interpreted. They show the probability of current and 
the next vigilance stages (i and j, respectively). If the transition 
process is completely random, the transition probabilities in 
row i and column j (pij) are the product of the column and row 
marginals (p.j and pi). The difference between the observed and the 
“no preference” predicted probabilities measures the specificity 
of i→j transition, i.e., how the transition from state i to state j is 
preferred compared to all other “j”-s. However, this difference 
still needs to be normalized, because a probability difference 
0.05 can be very impressive if pij = 0.1 and irrelevant if pij = 0.85. 
FIGURE 5 | Dependence of bout durations on time and treatment was modeled using linear mixed regression. Before the analysis, bout durations were transformed 
logarithmically and the linear model included time and treatment and their interactions as categorical variables. The figure shows the observed means and the 
back-transformed confidence intervals of the fitted means (shown by colored stripes). The time trends are visually different but the time x treatment interaction is 
significant only for PW and only in the 10-mg/kg dose group.
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The  normalized difference, the so-called z-statistic, is widely 
used in categorical data analysis to measure associations between 
variables. In the context of this study, minus z means that the i -> j 
transition is less likely to happen compared to the completely 
random alternative, meaning that the transition is somehow 
inhibited. Conversely, a high positive z is a sign of a preferred 
pathway. In Figure 6, the preferred and inhibited transitions 
between states are visualized by mapping z values to color a scale. 
The gray color in Figure 6 corresponds to those two cases when 
the z-s are not estimable because of the definition of variables 
(these are diagonal elements) or because there are fewer than five 
observations per cell. With the help of Figure 6, we can derive the 
probable bout trajectories by going row-wise and column-wise. 
For example, we can start in row-wise direction from PW. In the 
control group, in the first hour (upper left heat map), most of the 
traffic goes to AW (first column, dark red) followed by S1. The 
transition to S2 is strongly inhibited (dark blue). From S1, we can 
go back to PW (rose) or go further to S2 (also rose). Using the 
same upper left heatmap, we can also go in column-wise from 
bottom to up. Starting again from PW, we now see that PW is 
initiated mostly by impulses from AW (dark rose) followed by S1. 
S2 is dark blue again, suggesting that PW practically neither sends 
nor receives impulse from the state S2 directly. During the 3-h 
observation period, the traffic between AW and PW gradually 
redirected from dark red to close to neutral (white) in the Veh 
group, while it remains strongly connected in the treated groups. 
At the 5 mg/kg-dose level, the most prominent effect in the first 
hour is the lack of IS bouts followed by the disappearance of S2 
bouts after the larger dose. Figure 6 reveals several features that 
justify the distinction between REMS-S and REMS-L. REMS-L is 
very likely followed by an IS bout, which is not true for REMS-S. 
Both REMS-S and REMS-L bouts are suppressed in the first hour 
in all treatment groups, but the suppression remains prolonged 
only for REMS-L.
DISCUSSION
Santucci et al. (1996) have demonstrated that the CB1 antagonist 
SR141716A dose-dependently increased the time spent awake 
with a parallel suppression of NREMS and REMS in rats. 
Goonawardena et al. (2011) could not confirm these findings 
FIGURE 6 | The vigilance states do not randomly follow each other. Deviation from random order was quantified with z statistics. A high positive z value (dark red) 
indicates that a given state on the Y axis is more likely to transit to another state (on the X axis) compared to all others. The dark blue fields represent the opposite, 
i.e., the given state (on Y axis) is very unlikely to transit to a stage (on the X axis). For example, if PW was observed in the vehicle group, then, the most likely next 
stages are AW or S1 but S2 is very unlikely. The z statistic is not estimable if there is no transition (diagonal tiles) or there are too few (less than 5) observations in 
the cell. In these two cases, the tiles were colored dark gray. Z values that are larger than 2 or smaller than -2 are usually considered significant; however, this rule is 
based on large sample approximation.
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in rats with applying AM-251 in 2-mg/kg dose, although they 
have observed an increased REMS latency that suggests an 
inhibition of REMS generation. However, testing AM-251 and 
ABD459 (another CB1 antagonist) in 3-mg/kg dose showed that 
both drugs produced REMS-decreasing effect in mice, while 
wakefulness was increased by AM-251 only (Goonawardena et al., 
2015). In a recent study, dronabinol, a nonselective agonist of 
CB1/CB2 receptors, has been shown to decrease the percent time 
of REMS, and this effect was not reversible by either AM-251 
or the CB2 receptor antagonist AM-630. Also, none of the CB1 
and CB2 receptor antagonists could modify the sleep–wake 
pattern and the bout durations of NREMS and REMS items by 
applying alone (Calik and Carley, 2017). All these studies drew 
their conclusion by classifying vigilance states to REMS, NREMS, 
and wakefulness. For statistical comparisons, the authors used 
basic statistical tools, which, in principle, are applicable only for 
continuous variables (Santucci et al., 1996; Goonawardena et al., 
2011; Goonawardena et al., 2015; Calik and Carley, 2017). This 
is the so-called standard or conventional approach (McShane 
et al., 2010), which is widely criticized for not being sensitive 
enough and therefore leading to information loss. Several 
authors (Bizzotto et al., 2010; Kostyalik et al., 2014, Diniz Behn 
et al., 2010, Stephenson et al., 2013) suggested sophisticated 
models to overcome this problem. However, the proposed 
models require estimating a number of parameters, which is not 
an easy mathematical problem. The mathematical difficulties 
are multiplying in the presence of a drug effect that introduces 
additional time-dependent variations. This explains why these 
sophisticated models are very rarely used to assess drug effects. 
However, the simple approach proposed by McShane et al. (2010) 
seemed to provide a bypass from this deadlock, so we decided to 
test it using our data obtained with AM-251. First, we confirmed, 
in line with the literature, that AM-251 dose-dependently increases 
the time spent in AW at the expense of the amount of other states 
(Figure 1). Figure 1 represents our results obtained by the standard 
approach, and we started our exploratory investigations with plotting 
the histograms of bout durations (Figure 2). Figure 2 confirms that 
the distribution of bout durations in rats shows the same “spike 
and slab” characteristics described originally by McShane et al. 
(2010) in mice. This mixture distribution feature was the most 
pronounced for REMS, so we relabeled the REMS episodes as 
short and long REMS (REMS-S and REMS-L, respectively) using 
16 s (four epochs) as a cutoff. Note that the standard practice is to 
exclude all short REMS data from the analysis (Kitka et al., 2009). 
Figure 2 gives the impression that the shape of bout distributions 
in different vigilance stages remains unaffected by the treatments. 
If AM-251 had any effect on the average length of bout episodes, 
then, this effect would be apparent in Figure 2 by observing that 
the histograms of the treated groups are shifted horizontally 
relative to the control. However, such an effect could not be 
observed, which suggests that the frequencies rather than the 
duration times of bouts were affected. Therefore, in the next step, 
we focused on the relationships between time, drug treatment, 
and the frequencies of state transitions. Figure  3 shows the 
observed number of bouts by time and treatments. Strong time 
and dose dependency can be observed, practically for all vigilance 
states except PW. It is also noteworthy that, particularly in the 
first hour, several vigilance states, such as REMS-S, REMS-L, S2, 
and IS, are completely suppressed by the treatments. The ratio 
of bout numbers compared to the vehicle group is a plausible 
measure to assess the drug effect. We estimated this parameter 
using negative binomial regression (Figure 4). Figure 4 shows 
that the smaller dose of AM-251 selectively suppressed the 
REMS-L bouts, while increased the AW frequency moderately. 
With the double dose, the frequency of AW bouts is roughly 
doubled, while the frequency of all other states drops by 25–60% 
except PW. The effect of the drug on REMS-L is not significant, 
because the confidence interval width is too wide. The probable 
reason of the wide confidence interval for REMS-L is that both 
REMS-S and REMS-L bouts are suppressed even in the vehicle-
treated group, due to circadian factors in the regulation of the 
normal sleep–wake pattern. For this reason, the first hour of the 
study is uninformative (there is nothing to suppress), and there 
are too few observations. The analysis of the bout frequencies 
is based on the assumption that the multiplying effect of 
AM-251 on bout frequencies does not change with time. This 
is a reasonable assumption but could not be verified, because 
the regression procedure did not converge when the time × 
treatment interaction was included into the model. The probable 
reason of this, as shown in Figure 6, is that, particularly in the 
first hour, some type of bout events never happened or happened 
only for a very few times. For these vigilance states, the estimates 
are on the boundaries of the allowable parameter space and the 
optimization procedure is deemed to fail (Williamson et al., 
2013). Retrospectively, setting the time of drug administration at 
periods when the REMS activity is high would have been better 
to estimate the drug effect on the REMS periods. Indeed, we 
followed vigilance states only for 3 h after drug administration, 
which seems to be a limitation of our study compared to Santucci 
et al. (1996) and Goonawardena et al. (2015) who applied longer 
periods, 4 and 6 h, respectively. However, we used AM-251 
only as a tool to study the sleep effects of CB1 blockade effect. 
From this perspective, the change in concentration from 
pharmacokinetic reasons is a disturbing factor which interferes 
with the correct the evaluation of data. The estimated half-life 
of AM-251 is quite long (22 h) in rats (McLaughlin et al., 2013). 
Assuming a simple one-compartment model, this value gives 
that the relative difference between the initial maximum and 
the minimal concentration at the end of the observation period 
is 9.01%. Therefore, it is reasonable assuming that during the 
three-hour observation period, the plasma levels were relatively 
constant, and the time-dependent effects seen in Figures 3, 5, 
and 6 are not the result of the drug elimination.
The results presented so far suggested that the effect of 
AM-251 only modulates the between-states transitions. To 
check the lack of effect on bout duration, a regression analysis 
was conducted between bout duration and by treatment for each 
vigilance state. The effect of AM-251 on the bout duration of PW 
was highly significant, which is surprising, as PW is the only 
vigilance state that was completely resistant to the effect AM-251 
so far. However, we do not believe that this is a direct effect of 
AM-251 on neural circuits that are responsible for PW. We think 
this effect is a compensatory response as the difference from 
the control increases with time (Figure 5). If this were a direct 
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dose-related effect, then the time course would be the opposite. 
Essentially, the same effect was observed for S1. However, in this 
case, the compensatory decrease in bout duration was much 
more moderate (Figure 5).
McShane et al. (2013) introduced and demonstrated the 
usefulness of conditional analysis that is computing bout 
characteristics conditionally on the previous state. Since we have 
already known that AM-251 affects only the transition frequencies 
but not the state lengths, we investigated only the conditional 
dependence of transition frequencies. In the first step of the 
conditional analysis, we made a 7 × 7 table where the number 
in row i and column j showed the bout number of state j when 
the predecessor was state i. The “7” comes from the fact that we 
distinguished seven vigilance states, and states i and j can be any of 
them. This kind of table is known as a contingence table in statistics, 
and many methods were developed to visualize it. The goal of the 
visualization is to find connection between categorical variables 
which translates them, in the current context as that state i and state 
j (variables) are connected if state i precedes state j. We measured 
the strength of the connection with the help of z-statistics. High zij 
statistics means that statej is preferred over other states to “jump to” 
from the current state “i.” Large negative z means just the opposite—
namely, the transition from “i” to “j” is not likely. When the matrix 
of z-s was visualized by mapping the zij -s to color, the resulting 
“transition heatmaps” turned to be very informative (Figure 6). 
Most of the z values were significantly positive and significantly 
negative (above 2 or below -2, respectively). Therefore, transitions 
between states generally cannot be considered random. In fact, 
we identified several regular features, characteristics for each map 
regardless of time or drug treatment. The heatmaps helped us 
easily discover highly connected vigilance stages and derive the 
likely bout trajectories. The drug, time, and circadian effect can 
be easily spotted on them. Taken together, we recommend using 
the transition heatmaps as explorative aids for the visualization 
of transitions between vigilance stages that can be a useful in the 
microstructure analysis of sleep research.
CONCLUSION
AM-251 selectively modulates the frequency of transitions 
between vigilance stages without affecting the bout durations. It 
increases the transition to AW and suppresses the transitions to 
all other stages except to PW. Conversely, the durations of PW 
episodes are decreased, but the profile of this effect suggests an 
indirect compensatory action. The effect on sleep transitions 
was visualized using a newly developed tool we call transition 
heatmap. We believe that the easily computable transition 
heatmaps can be useful for exploring the microstructure of sleep–
wake architecture.
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